Medication Guide

In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.

Erlotinib(Tarceva)

It is mainly indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring specific gene mutations (EGFR exon 19 deletion or exon 21 L858R substitution mut···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：32
Everolimus(Afinitor)

Indicated for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer; neuroendocrine tumors of pancreatic, gastrointestinal, and pulmonary origin; advance···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：31
Gefitinib(Iressa)

It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have been confirmed to harbor EGFR exon 19 deletions or exon 21 (L8···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：29
Idelalisib(Zydelig)

A kinase inhibitor used in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：58
Infigratinib(Truseltiq)

It is indicated for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene abnormalities.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：56
Lazertinib(Leclaza)

It is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EG···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：41
Lenacapavir(Sunlenca)

In combination with other antiretroviral drugs, it is indicated for the treatment of heavily treated adult HIV-1-infected patients with multidrug resistance whose current antiretro···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：31
Lenalidomide(Revlimid)

It is used for the treatment of various hematological diseases such as multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lym···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：43
Obeticholic(Ocaliva)

It is indicated for the treatment of adult patients with primary biliary cholangitis who have an inadequate response to or are intolerant of ursodeoxycholic acid (UDCA), and who ha···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：40
Lusutrombopag(Mulpleta)

It is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who develop the condition prior to undergoing surgery.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：59
Macitentan(Opsumit)

It is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH, WHO Group 1) to reduce the risk of disease progression and hospitalization.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：54
Mavacamten(Camzyos)

It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) Class Ⅱ-Ⅲ, to imp···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：55

home page previous 48 48/101 next last page

News

The U.S. FDA approved the combination of Pembrolizumab and Enfortumab vedotin-ejfv for the treatment
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】

Recommended：[list:visits]2025-17-12
Lucius Pharmaceuticals Laos launched lorlatinib, a third-generation targeted drug for lung cancer
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】

Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic D
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】

Recommended：[list:visits]2026-24-07
How Are the Price and Effect of Lucius Generic Drugs from Laos? Summary of Real Patient Feedback on
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】

Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now available
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】

Recommended：[list:visits]2026-21-07
Is Lucius Pharma (Laos) Reliable? A Comprehensive Analysis of GMP Certification, WHO Inspection, and
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】

Recommended：[list:visits]2026-20-07
How is Lucius Pharmaceutical in Laos? Established 5 Years, 200+ Generic Drug Varieties, 54 Anti-Canc
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】

Recommended：[list:visits]2026-17-07
Laos is becoming the "world's pharmacy"? A full analysis of the generic drug industry
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】

Recommended：[list:visits]2026-16-07

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More